Thomas Edwards, MD
Family Medicine · Thomasville, GANPI 1558599159
Payments from drug & device makers
Across 161 payments — averaging $18.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$376
- Pfizer$337
- Dexcom, Inc.$336
- GSK$196
- Corium, LLC$167
- Almatica Pharma LLC$131
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,939100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 20 | $376 |
| Pfizer | 20 | $337 |
| Dexcom, Inc. | 15 | $336 |
| GSK | 12 | $196 |
| Corium, LLC | 9 | $167 |
| Almatica Pharma LLC | 8 | $131 |
| AstraZeneca | 8 | $122 |
| AbbVie | 6 | $119 |
| Lilly USA, LLC | 6 | $101 |
| Seqirus USA Inc | 5 | $92 |
| Otsuka America Pharmaceutical, Inc. | 5 | $82 |
| Astellas Pharma US Inc | 5 | $76 |
| Amgen | 4 | $74 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $71 |
| Axsome Therapeutics, Inc. | 3 | $71 |
| Ironshore Pharmaceuticals Inc. | 3 | $69 |
| Sanofi Pasteur Inc. | 2 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $42 |
| Exact Sciences | 2 | $38 |
| Sumitomo Pharma America, Inc. | 2 | $38 |
| Boehringer Ingelheim | 2 | $34 |
| Johnson & Johnson | 2 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| Radius Health, Inc. | 1 | $32 |
| Grifols USA, LLC | 1 | $31 |
| Hologic Sales And Service, LLC | 2 | $28 |
| Novartis | 1 | $24 |
| Linus Health, Inc. | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Corcept Therapeutics | 1 | $19 |
| Abbott | 1 | $19 |
| Inari Medical, Inc. | 1 | $19 |
| Vertex | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$2,951 in reported general payments places this provider in the 75th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 176 | $224,914 |
| JardianceEmpagliflozin | 154 | $139,063 |
| EliquisApixaban | 115 | $118,578 |
| MounjaroTirzepatide | 106 | $115,602 |
| LinzessLinaclotide | 116 | $83,213 |
| FarxigaDapagliflozin Propanediol | 96 | $81,162 |
| RybelsusSemaglutide | 45 | $56,570 |
| TrulicityDulaglutide | 34 | $32,182 |
| CreonLipase/Protease/Amylase | 17 | $28,552 |
| BelsomraSuvorexant | 63 | $26,535 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $24,787 |
| TradjentaLinagliptin | 23 | $21,995 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 37 | $19,063 |
| UbrelvyUbrogepant | 11 | $18,495 |
| MyrbetriqMirabegron | 23 | $15,365 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $376 | $281,484221 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $34 | $167,093189 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $101 | $150,607159 claims |
| AbbVieLinzess, Creon, Ubrelvy, Synthroid | $119 | $134,018200 claims |
| PfizerEliquis | $337 | $118,578115 claims |
| AstraZenecaFarxiga | $122 | $81,16296 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Shingrix | $196 | $33,84888 claims |
| Astellas Pharma US IncMyrbetriq | $76 | $15,36523 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $38 | $9,73217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Thomasville
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.